



#14

Sheet 1 of 1		PTO/SB/08A		ATTY DOCKET NO. 38005-0147		SERIAL NO. 09/842,316	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT KOSTENIS <i>et al.</i>			
				FILING DATE April 26, 2001		GROUP Unassigned	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE (M/D/Y)	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE (M/D/Y)	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
2	A1	WO 00/22129	04/20/00	PCT	1	1	
2	A2	WO 00/11166	03/02/00	PCT	1	1	
2	A3	WO 99/19513	04/22/99	PCT	1	1	
2	A4	WO 01/04139 A2	01/18/01	PCT	1	1	
2	A5	EP 1 090 925 A1	04/11/01	EPO	1	1	
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
2	A6		Hla et al., "Sphingosine-1-Phosphate Signaling via the EDG-1 Family of G-Protein-Coupled Receptors", Annals New York Academy of Sciences, pp. 16-24				
2	A7		Im et al., "Characterization of a Novel Sphingosine 1-Phosphate Receptor, Edg-8", The Journal of Biological Chemistry, May 12, 2000, Vol. 275, No. 19, pp. 14281-14286				
2	A8		Glickman et al., Molecular Cloning, Tissue-Specific Expression, and Chromosomal Localization of a Novel Nerve Growth Factor-Regulated G-Protein-Coupled Receptor, nrg-1", Molecular and Cellular Neuroscience 14, pp. 141-152, 1999				
2	A9		An et al., "Signaling Mechanism and Molecular Characteristics of G Protein-Coupled Receptors for Lysophosphatidic Acid and Sphingosine 1-Phosphate", Journal of Cellular Biochemistry Supplements, 30/31, pp. 147-157, 1998				
2	A10		Im et al., "Homo sapiens sphingosine 1-phosphate receptor Edg-8 gene, complete cds", Database EM_HUM Online, 1 p., December 6, 2000				
2	A11		Ebi, "Homo sapiens chromosome 19 clone CTC-429L19, Working Draft Sequence, 4 Ordered Pieces, 13 pgs. October 8, 1999				
EXAMINER				DATE CONSIDERED 3-31-03			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

file



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

Complete If Known

Application Number	09/842,316
Filing Date	April 26, 2001
First Named Inventor	KOSTENIS et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0147

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
✓	B1	AN et al.; Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphatidic Acid; The Journal of Biological Chemistry, vol. 273, No. 14, Issue of April 3, pp. 7906-7910, 1998	
✓	B2	AN et al.; Sphingosine 1-Phosphate-induced Cell Proliferation, Survival, and Related Signaling Events Mediated by G Protein-coupled Receptors Edg3 and Edg5; The Journal of Biological Chemistry, vol. 275, No. 1, Issue of January 7, pp. 288-296, 2000	
✓	B3	AN et al., Transduction of Intracellular Calcium Signals through G Protein-Mediated Activation of Phospholipase C by Recombinant Sphingosine 1-Phosphate Receptors; The American Society for Pharmacology and Experimental Therapeutics, pp 787-794; (1999)	
✓	B4	ANCELLIN et al., Differential Pharmacological Properties and Signal Transduction of the Sphingosine 1-Phosphate Receptors EDG-1, EDG-3, and EDG-5 vol. 274, No. 27, Issue of July 2, pp. 18997-19002, (1999)	
✓	B5	OKANO et al., Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression in Myelin-Deficient Mutant Mouse; Journal of Neurochemistry, Vol. 56, No. 2, 1999 pp. 560-567	
✓	B6	BARBAS III et al., Combinatorial Immunoglobulin Libraries on the Surface of Phage (Phabs): Rapid Selection of Antigen-Specific Fabs; Methods A Companion to Methods in Enzymology, vol. 2, no. 2, April, pp 119-124, (1991)	
✓	B7	BITTER et al., Expression and Secretion Vectors for Yeast; Methods in Enzymology, vol. 153, pp 516-544	
✓	B8	BUNEMANN et al., A Novel Membrane Receptor with High Affinity for Lysosphingomyelin and Sphingosine 1-phosphate in Atrial Myocytes; The EMB Journal vol. 15. no. 20 pp 5527-5534, 1996	
✓	B9	CARTER et al./ Humanization of an Anti-p185...; Proc. Natl. Acad. Sci USA; vol. 89, pp 4285-4289, May 1992	
✓	B10	CHAO et al.; Sphingosine-mediated Phosphatidylinositol... The Journal of Biological Chemistry, vol. 269, No. 8, February 25, 1994; pp 5849-5856	
✓	B11	COONEY et al.; Site Specific Oligonucleotide Binding... Science, vol. 241; pp 456-459	

Examiner
Signature

Date
Considered

3-31-01

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 28 2003



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	09/842,316
Filing Date	April 26, 2001
First Named Inventor	KOSTENIS
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0147

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	B12	CORPET, Multiple Sequence Alignment...; Nucleic Acids Research; Vol. 16, 1988; pgs. 10881-10890	
✓	B13	COTTON; Reactivity of Cytosine...; Proc. Natl. Acad. Sci., Vol. 85, pp. 4397-4401; 6/1988	
✓	B14	DERVAN et al.; Second Structural Motif ...; Science, Vol 251; pgs 13601363; 1991	
✓	B15	DURIEUX et al./ Responses to Sphingosine-1...; Amer. Physio. Society; pgs 1360-1364	
✓	B16	GHOSH et al., Sphingosine 1-Phosphate...; Journal of Biological Chemistry; vol. 269, No. 36, 9/1994; pp. 22628-22635	
✓	B17	GLICKMAN et al.; Molecular Cloning...; Molecular and Cellular Neuroscience 14, pgs. 141-152 (1999)	
✓	B18	GOHLA et al.; Differential Involvement of...; The Journal of Biological Chemistry; Vol. 274, No. 25, 6/18 1999; pp. 17901-17907	
✓	B19	GONDA; The Novel Sphingosine...; Biochem J. (1999) 337, 67-75	
✓	B20	GREEN et al., Antigen-Specific Human Monoclonal...; Nature Genetics, vol. 7, 5/1994; pgs 13-21	
✓	B21	GUEGUEN et al.; Structure -Activity Analysis...; Biochemistry 199, 38, 8440-8450	
✓	B22	HISANO et al., Induction and Suppression...; Blood, Vol 93, No. 12; June 15, 1999; pp 4293-4299	

Examiner
Signature

Date
Considered


3-31-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 28 2003
TECH CENTER 1600/2900



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/842,316
		Filing Date	April 26, 2001
		First Named Inventor	KOSTENIS et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	38005-0147
Sheet	3	of	8

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B23	Nordstrom et al.; Translational Control By Antisense...; Gene, 72 (1988) 237-240	
	B24	HIGGINS et al., Fast and Sensitive Multiple...; Cabios Communications; vol. 5, no. 2, 1989 pp 151-153	
	B25	HLA et al., Sphingosine-1...; Biochemical Pharm; vol. 58, pp. 201-207; 1999	
	B26	HLA et al.; An Abundant Transcript...; Journal of Biological Chemistry; vol. 265, No. 16; 1990; pp. 9308-9313	
	B27	HUANG et al., Parallelization of Local...; Cabios; vol. 8, no. 2, 1992, pgs 155-165	
	B28	IM et al., Molecular Cloning and...; Computer Applications in the Biosciences; 8:1-06 (1992)	
	B29	JALINK et al.; Lysophosphatidic Acid...; Biochem Biophys. Acta 1198:185 (1994)	
	B30	JALINK et al., Biochem Biophysica Acta; 1198 (1994) 185-196	
	B31	JONES et al., Replacing the Complementarity...; Nature Vol. 321; 5/1986; pgs. 522-525	
	B32	KON et al., Journal of Biological Chemistry; Vol. 274, No. 34, 8/1999; pp. 23940-23947	
	B33	KOHLER et al.; Continuous Cultures...; Nature Vol. 256, August 1975; pgs 495-497	

Examiner Signature		Date Considered	3-31-01
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 23 2003
TECH CENTER 1600/2900



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 8

Complete if Known

Application Number	09/842,316
Filing Date	April 26, 2001
First Named Inventor	KOSTENIS et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0147

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2	B34	KOSTENIS et al., The N-Terminal Extension; The Journal of Biological Chemistry; vol. 272, No. 31, 1997; pp. 19107-1911	
2	B35	LEE et al., Complexes Formed By...; Nucleic Acids Research; vol. 6, no. 9; 1979; pgs 3073-3091	
2	B36	LEE et al., The Inducible G Protein...; Journal of Biological; vol. 271, No. 19; May 1996; pp. 11272-11279	
2	B37	LEE et al., Sphingosine-1-Phosphate...; Science, Vol. 279; March 1998; pp 1552-1555	
2	B38	LEE et al., Lysophosphatidic Acid...; Journal of Biological Chemistry; vol. 273, no. 34, 8/1998, pp. 22105-22112	
2	B39	LEE et al., Vascular Endothelial...; Cell, Vol. 99, 301-312, October 1999	
2	B40	LONBERG et al., Antigen-Specific Human...; Nature, vol. 368, April 1994, pgs 856-859	
2	B41	LOSMAN et al., Baboon Anti-Idiotypic Antibodies...; Int. J. Cancer, 46, pgs 310-314, 1990	
2	B42	LYNCH et al., Life On The edge...; Elsevier Science Ltd., 1999, vol. 20; pgs. 473-475	
2	B43	MATTIE et al., Sphingosine-1-Phosphate...; Journal of Biological Chemistry; vol. 269, No. 5, February 1994; pp. 3181-3188	
2	B44	HERINGDORF et al., Calcium Signalling...; Naunyn-Schmiedeberg's Arch Pharmacol (1996) pp. 397-403	

Examiner
Signature

Date
Considered


7-31-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 23 2003
TECH CENTER 1600/2900



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	09/842,316
Filing Date	April 26, 2001
First Named Inventor	KOSTENIS et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	38005-0147

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2	B45	MOOLENAAR et al., Lysophosphatidic Acid...; Current Opinion in Cell Biol 9: pp. 168-173 (1997)	
2	B46	MORRIS; One Wheel On My Wagon...; Trends Pharmacol Science 20; pp. 393-395, (1999)	
2	B47	MYERS et al., Detection of Single Base...; Science, vol. 230; pp. 1242-1246, (1985)	
2	B48	NEEDLEMAN et al., A General Method Applicable...; J. Mol Biol. (1970) 48, pp 443-353	
2	B49	NOH et al., Different Signaling Pathway...; Journal of Cellular Physiology 176; (1999) pp. 412-423	
2	B50	OKAJIMA et al., Involvement of Pertussis...; J. Biol Chem 273; (1998) pp 260-264	
2	B51	OKAMOTO et al., EDG1 Is a Functional...; Journal of Biological Chemistry; vol. 273, No. 42, pp. 27104-27110, (1998)	
2	B52	ORLANDI et al., Cloning Immunoglobulin...; Proc. Natl. Acad. Scie, vol. 86, pp. 3833-3837, May 1989	
2	B53	PEARSON; Using the FASTA Program...; Methods in Molecular Biology 24; pp. 306-331 (1994)	
2	B54	PEARSON et al., Improved Tools for...; Proc. Natl. Acad. Sci., vol. 85, pp. 2444-2448, April 1988	
2	B55	POSTMA et al., Sphingosine-1-...; The EMBO Journal; vol. 15 no. 10 pp. 2388-2395, 1996	

Examiner
SignatureDate
Considered

3-31-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 23 2003
TECH CENTER 1600/2900



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
		Application Number	09/842,316
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	April 26, 2001
		First Named Inventor	KOSTENIS et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	38005-0147
Sheet	6	of	8

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B56	PYNE et al., Sphingosine 1-phosphate; Biochem J. (2000) 349, 385-402	
	B57	SADAHIRA et al., Sphingosine 1-phosphate...; Proc. Natl. Acad. Sci. vol. 89, pp. 9686-9690, October 1992	
	B58	RIZZA et al., Lysophosphatidic Acid...; Laboratory Investigation, vol. 79, no. 10, pp 1227-1233, 1999	
	B59	SAIKI et al., Analysis of Enzymatically...; Nature vol. 324, 1986, pp. 163-166	
	B60	SCHULZE et al., Lysophosphatidic Acid Increases...; Journal of Neurochemistry; vol. 68, No. 3, 1997, pp. 992-1000	
	B61	SIESS et al., Lysophosphatidic Acid... Proc. Natl. Acad. Sci., vol. 96, pp. 6931-6936, 1999	
	B62	SMITH et al., Comparison of Biosequences; Advances In Applied Mathematics 2, pp. 482-489; (1981)	
	B63	TOKUMURA et al., Stimulatory Effect of...; Arch. Int. Pharmacodyn. 245, pp. 74-83 (1980)	
	B64	TOKUMURA et al., Vasopressor Effect of...; Research Communications in Molecular Pathology and Pharmacology; vol. 90, No. 1, October 1995	
	B65	TORNQUIST et al., Sphingosine 1-Phosphate ...; Endocrinology, vol. 138, No. 10, pp. 4049-4057	
	B66	VAN BROCKLYN et al., Sphingosine-1-phosphate...; Blood, vol. 95, No. 8, (April 2000)	

Examiner Signature		Date Considered	3-31-03
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 28 2003
TECH CENTER 1600/2900



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/842,316
		Filing Date	April 26, 2001
		First Named Inventor	KOSTENIS et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 7 of 8	Attorney Docket Number	38005-0147	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B67	van KOPPEN et al., Activation of High Affinity: The Journal of Biological Chemistry; vol. 271, no. 4, pp. 2082-2087, 1996	
	B68	XIA et al., Activation of Sphingosine Kinase...; The Journal of Biological Chemistry; vol. 274, no. 48, November 1999; pp. 34499-34505	
	B69	YAMAZAKI et al., Egg-6 as a Putative... Biochemical and Biophysical Research Communications 268, pp. 583-589 (2000)	
	B70	YATOMI et al., Sphingosine 1-Phosphate...; J. Biochem, 121, pp. 969-973 (1997)	
	B71	YATOMI et al., Sphingosine 1-Phosphate...; J. Biochem, vol. 272, No. 8, pp. 5291-5297, 1997	

Examiner Signature	Date Considered 3-31-03
--------------------	-------------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.